Remsima, a biosimilar of Remicade (infliximab), was granted a marketing authorization throughout the European Union in 2013. Last week, Merck reported a 30% drop in Remicade first-quarter sales due to “the accelerating impact of biosimilar competition in the company’s marketing territories in Europe.” This will likely be the trend as additional biosimilar products become approved globally. In fact, Citigroup analysts estimate that innovative biologics will lose $110 billion in sales to copycats by 2025.
Stay tuned to the Big Molecule Watch for further developments.